Reducing the minimum detectable change in vastus lateralis fat fraction using MRI in clinical trials for Duchenne muscular dystrophy (DMD) therapy

被引：0
|
作者：
Hammond, M. [1 ]
Roche, F. [2 ]
Harris, J. [1 ]
Luna, B. [1 ]
Mary, J. [2 ]
Berger, M. [1 ]
Vincent, F. [2 ]
Zabbatino, S. [1 ]
Heinichen, L. [3 ]
Scheyer, R. [3 ]
Holland, S. [1 ]
机构：
[1] Medpace Core Labs, Cincinnati, OH USA
[2] Medpace Core Labs, Lyon, France
[3] Medpace, Cincinnati, OH USA
来源：
NEUROMUSCULAR DISORDERS | 2021年 / 31卷
关键词：
D O I：
10.1016/j.nmd.2021.07.360
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
EP.335
引用
收藏
页码：S152 / S152
页数：1
相关论文
共 49 条
  • [1] Sources of variability in vastus lateralis fat fraction measurements using MRI in clinical trials for Duchenne muscular dystrophy (DMD) therapy
    Hammond, M.
    Roche, F.
    Mary, J.
    Berger, M.
    Vincent, F.
    Zabbatino, S.
    Scheyer, R.
    Peterson, M.
    Holland, S.
    NEUROMUSCULAR DISORDERS, 2020, 30 : S92 - S92
  • [2] MRI vastus lateralis fat fraction predicts loss of ambulation in Duchenne muscular dystrophy
    Naarding, Karin J.
    Reyngoudt, Harmen
    van Zwet, Erik W.
    Hooijmans, Melissa T.
    Tian, Cuixia
    Rybalsky, Irina
    Shellenbarger, Karen C.
    Le Louer, Julien
    Wong, Brenda L.
    Carlier, Pierre G.
    Kan, Hermien E.
    Niks, Erik H.
    NEUROLOGY, 2020, 94 (13) : E1386 - E1394
  • [3] Translation related clinical trials in duchenne muscular dystrophy (DMD) in the UK
    Choudhury, R.
    Barreto, G.
    Ganeshaguru, K.
    Cirax, S.
    Scoto, M.
    Muntoni, F.
    Guglieri, M.
    Straub, V.
    Bell, G.
    Speed, C.
    Bourke, J.
    Bushby, K.
    Quinlivan, R.
    Jones, R.
    Hunt, A.
    NEUROMUSCULAR DISORDERS, 2010, 20 : S6 - S7
  • [4] Longitudinal changes in fat fraction histograms using quantitative MRI in Duchenne muscular dystrophy
    Reyngoudt, H.
    Baudin, P.
    Araujo, E. Caldas de Almeida
    Wong, B.
    Carlier, P.
    Marty, B.
    NEUROMUSCULAR DISORDERS, 2022, 32 : S66 - S67
  • [5] Minimal detectable change in the North Star ambulatory assessment (NSAA) in Duchenne muscular dystrophy (DMD)
    Muntoni, F.
    Manzur, A.
    Mayhew, A.
    Signorovitch, J.
    Sajeev, G.
    Yao, Z.
    Dieye, I.
    Jenkins, M.
    Ward, S.
    NEUROMUSCULAR DISORDERS, 2018, 28 : S121 - S121
  • [6] Clinical approaches in the treatment of Duchenne muscular dystrophy (DMD) using oligonucleotides
    Bertoni, Carmen
    FRONTIERS IN BIOSCIENCE-LANDMARK, 2008, 13 : 517 - 527
  • [7] MRI muscle segmentation in Duchenne muscular dystrophy (DMD): Stepwise region of interest (ROI) contractions to minimize fat fraction variability
    Hammond, M.
    Murthy, S.
    Harris, J.
    Luna, B.
    Roche, F.
    Berger, M.
    Vincent, F.
    Zabbatino, S.
    Scheyer, R.
    Heinichen, L.
    Holland, S.
    NEUROMUSCULAR DISORDERS, 2022, 32 : S67 - S67
  • [8] Development and evaluation of a time to event endpoint for clinical trials in Duchenne muscular dystrophy (DMD)
    McDonald, C.
    Muntoni, F.
    Marden, J.
    Goemans, N.
    Gomez-Lievano, A.
    Zhang, A.
    Ward, S.
    Signorovitch, J.
    NEUROMUSCULAR DISORDERS, 2022, 32 : S69 - S69
  • [9] Monoclonal antibodies for clinical trials of Duchenne muscular dystrophy therapy
    Le Thanh Lam
    Nguyen Thi Man
    Morris, Glenn E.
    NEUROMUSCULAR DISORDERS, 2014, 24 (03) : 195 - 200
  • [10] MRI fat fraction distribution in Duchenne muscular dystrophy (DMD): effect size comparison to identify optimal biomarker for early efficacy assessment
    Hammond, M.
    Harris, J.
    Luna, B.
    Roche, F.
    Vincent, F.
    Berger, M.
    Zabbatino, S.
    Scheyer, R.
    Holland, S.
    NEUROMUSCULAR DISORDERS, 2023, 33 : S80 - S80
12345